Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DISC 0998

Next Previous
X
Search
Drug Profile

DISC 0998

Alternative Names: DISC-0998

Latest Information Update: 27 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Developer Disc Medicine
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action HFE2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anaemia

Most Recent Events

  • 21 Mar 2024 Disc Medicine has PCT patent application for DISC 0974 in the multiple countries worldwide
  • 21 Mar 2024 Disc Medicine has two pending PCT patent applications and one pending US patent application for "composition of matter, method of treatment and use claims related to initial indications, anemia of myelofibrosis and chronic kidney disease as well as other indications, e.g., anemia of inflammatory bowel disease and other anemias of chronic disease involving iron restriction from elevated hepcidin."
  • 21 Mar 2024 Disc medicine in-licensed a patent family from AbbVie

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top